Saturday, July 28, 2007

Freeman Dyson on our biotech future

Biotech News
AZhttp, Inc.

Freeman Dyson on our biotech future
By George Elvin
dyson.jpg Freeman Dyson writes on "Our Biotech Future" and green technology in the New York Times Review of Books. "I predict that the domestication of biotechnology will dominate our lives during the next fifty years at least as much ...
http://www.greentechforum.net/category/news/2007/07/27/freeman-dyson-on-our-biotech-future/

Biotechnology Marketing

Biotech & Medical Stocks

Friday's Top Biotech & Medical Stocks
By HSA(HSA)
by HS Ayoub BioHealth Investor Biotechnology HEMOBIOTECH INC [HMBT.OB] +27.50% TARGACEPT, INC. [TRGT] +19.89% REXAHN PHARMACEUTICL [RXHN.OB] +10.59% ANIKA THERAPEUTICS [ANIK] +8.58% GENETIC TECH SPON [GENE] +7.88% Diagnostic. ...
http://biohealthinvestor.com/2007/07/fridays-top-biotech-medical-stocks_27.html


Biotech News
AZhttp, Inc.
Biotechnology Marketing

Biotech sector sets standards

Biotech News

Biotech sector sets standards, seeks to ease fears Reuters South Africa - Johannesburg,South Africa By Carey Gillam KANSAS CITY, Missouri (Reuters) - US biotech crop companies on Wednesday unveiled a plan for new industry standards at a time when the ...
http://africa.reuters.com/business/news/usnBAN628564.html


AZhttp, Inc.


Biotechnology Marketing

Friday, July 27, 2007

Report offers tips for a successful biotechnology sector Cordis News - Brussels,Belgium Money and size alone are not enough to foster the development

Report offers tips for a successful biotechnology sector Cordis News - Brussels,Belgium Money and size alone are not enough to foster the development of a strong biotechnology sector, according to a new report from the European Commission. ...
http://cordis.europa.eu/fetch?CALLER=EN_NEWS&ACTION=D&SESSION=&RCN=28100

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Hydrolysis

Biotech News
AZhttp, Inc.

Hydrolysis
A definition for enzyme hydrolysis, to explain what kind of biochemical reaction hydrolases catalyze and how that is useful to biotechnology applications.
http://biotech.about.com/od/glossary/g/hydrolysis.htm

Biotechnology Marketing

Tucson biotech firm is being bought out

Biotech News

Tucson biotech firm is being bought out

A Seattle-based cancer-drug company spotted promise in a firm born in Arizona's developing biotech industry, and is snapping it up.
Tucson- and Scottsdale-based Systems Medicine Inc. will become a wholly owned subsidiary of Cell Therapeutics Inc. when the buyout is complete, the companies announced Wednesday.

Arizona Daily Star - Tucson,AZ,USA
By Tim Steller A Seattle-based cancer-drug company spotted promise in a firm born in Arizona's developing biotech industry, and is snapping it up.
...
http://www.azstarnet.com/business/193389


AZhttp, Inc.
Biotechnology Marketing

Biotech park upsets residents

Biotech News

Biotech park upsets residents

A plan to build a sprawling $800 million biotechnology park adjacent to Johns Hopkins Hospital has some East Baltimore residents worried that they will not be able to afford to buy new homes in the area despite the roughly $150,000 they will receive for homes that will be demolished to make way for offices, shops and residences.

Baltimore Sun - United States

As part of the project, some residents are receiving additional training and education so that they can get jobs at the new biotech park and perhaps ...





Biotechnology Marketing

Thursday, July 12, 2007

Kane Biotech Announces Positive Results From an Independent Wound Care Study

Biotech News


Kane Biotech Announces Positive Results From an Independent Wound Care Study
Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce positive results from an in vitro study using a novel approach to treat chronic wound infections with a combination of DispersinB and lytic bacteriophage.

Marketing Firm


The study carried out by Dr. Randy Wolcott's team at the Southwest Regional Wound Care Center in Lubbock, Texas, showed that the combination of DispersinB with a bacteriophage mixture was very effective against biofilm-embedded E.coli. More specifically, the DispersinB and bacteriophage mixture showed almost 99% inhibition of E.coli growth and proliferation as compared to only 9% inhibition by the bacteriophage mixture alone over the four day period of treatment. While DispersinB makes biofilm-embedded bacteria more susceptible to bacteriophage by inhibiting or dispersing biofilms, lytic bacteriophage invades bacterial cells and disrupts the metabolism of the bacteria. This combination therapy could provide a new and highly effective method of treating chronic wounds such as diabetic foot ulcers.

"DispersinB degrades the defences of the biofilm, providing a synergistic effect when combined with bacteriophages. Our findings are very encouraging as DispersinB may also enhance the effectiveness of a number of antimicrobial agents in the treatment of chronic wounds" stated Dr. Wolcott. "I believe that DispersinB will also prove effective against other wound infection associated bacteria in combination with other antimicrobials and we are continuing our studies in this area."

"DispersinB is one of our lead technologies to prevent and disperse biofilms and is proving to have very broad applications in the medical field. This study adds further evidence to the growing knowledge base on the value of our technology", stated Gord Froehlich, President and CEO of Kane Biotech.

Chronic wounds are a serious debilitating complication of vascular disease, diabetes and prolonged immobility and are a huge unmet clinical need that costs the US health care system $20 billion per year. The current global market for wound care management technology is estimated at US$4.5 billon per year.

"Our DispersinB technology prevents and removes biofilms while the bacteriophages and antimicrobial agents offer broad spectrum microbial control. As a naturally occurring non-antibiotic antibiofilm enzyme, DispersinB is a compelling technology for clinical settings", added Mr. Froehlich.

About Dr. Randy Wolcott

Randall Wolcott, M.D., P.A., is the founder and medical director of the Southwest Regional Wound Care Center in Lubbock, Texas. The focus of Dr. Wolcott's clinical practice and research is wound healing. He is an expert in biofilm-based chronic wound management and was instrumental in initiating the research on chronic wounds at the Center for Biofilm Engineering (CBE) Bozeman, MT. Dr. Wolcott, CBE and the University of Washington received a $2.9 million grant from the National Institutes of Health (NIH, USA) in 2006 to find new ways to heal chronic wounds.

About the Southwest Regional Wound Care Center

The Southwest Regional Wound Care Center, located in Lubbock, Texas, is dedicated to healing wounds. As a leader in treating hard to heal wounds, everything the Center does is carefully designed to nurture, always putting the patient first. The Center specializes in wound healing using a biofilm-based wound care approach and treats up to 100 patients per day. The medical staff includes a physician, physician assistants, nurses, social workers, physical therapists, licensed vocational nurses (LVNs), certified hyperbaric oxygen technicians and clinical technicians.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse microbial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria and other microorganisms become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay. Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.


Biotechnology Marketing

Wednesday, July 11, 2007

California's Biotech Industry

California's Biotech Industry
Several major biotechnology hubs exist in North America, one of which can be found on the US west coast, in California. Previously well-known for it's high tech industry, and the...
http://biotech.about.com/b/a/000056.htm


Biotech News
AZhttp, Inc.
Biotechnology Marketing

Biotech News - Biotech Stocks

Biotech News

Georgia Biotech Company Lands First Venture Financing WRAL.com - Raleigh,NC,USA Abeome Corporation, a biotech company developing antibody technology, has closed on its first venture financing. The firm, which had earlier received ...
http://www.wral.com/business/local_tech_wire/venture/story/1577108/


Tercica (TRCA): More Small Cap BioTech Madness
24/7 Wall St. - New York,NY,USA
Tercica (TRCA) is a small biotech which had an operating loss of $86 million last year on revenue of a little over $1 million. The year's numbers have not ...
http://www.247wallst.com/2007/07/tercica-trca-mo.html

AZhttp, Inc.

Sector Glance: Biotech Stocks Fall
Forbes - NY,USA
AP 07.10.07, 4:12 PM ET Shares of biotechnology companies traded slightly lower Tuesday on a day of light news, as the sector edges closer to the beginning ...
http://www.forbes.com/feeds/ap/2007/07/10/ap3900472.html


Turnaround Time for Biotech?
Motley Fool - USA
Since then, biotech stocks have experienced a bit of volatility. According to SmartMoney's Sector Tracker, biotechs were up a collective 10% for the year ...
http://www.fool.com/investing/high-growth/2007/07/10/turnaround-time-for-biotech.aspx



Biotechnology Marketing


Tuesday's Top Biotech & Medical Stocks
By HSA(HSA)
by HS Ayoub BioHealth Investor Biotechnology SAMARITAN PHARMA [LIV] +21.30% CARDIOVASCULAR BIOTH [CVBT.OB] +10.58% SEQUENOM INC [SQNM] +9.80% NEURALSTEM INC [NRLS.OB] +9.60% NASTECH PHARM CO [NSTK] +7.22% Diagnostic. ...
http://biohealthinvestor.com/2007/07/tuesdays-top-biotech-medical-stocks_10.html

Dade moves to take back biotech land

Biotech News
AZhttp, Inc.

Dade moves to take back biotech land
Miami Herald - Miami,FL,USA
Kendrick Meek, moved to secure millions in federal dollars for the biotech park. Since then, Carrie Meek has returned the car and vowed ... http://www.miamiherald.com/416/story/166467.html


Biotechnology Marketing

Wednesday, July 04, 2007

Genetic Mutation and Cancer Therapy

Biotech News
AZhttp, Inc.

Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics


Recurring mutation found in breast, colorectal and ovarian cancers

07-04-2007

Phoenix, July 4, 2007--Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) today announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers. The altered form of AKT1 appears to cause tumor cell proliferation and may play a role in making cells resistant to certain types of therapies. The findings are reported in an advance online publication (AOP) of the journal Nature.
The PI3-Kinase/AKT pathway is among the most commonly activated cellular pathways in human cancers and members of this pathway are among the most frequently targeted for new cancer drug discovery efforts. Activation of this pathway results in cancer cell growth and cell survival. Although AKT1 is central to pathway activation, its role in cancer has been that of an intermediary between mutated upstream regulatory proteins and downstream survival signaling proteins. This is the first evidence of direct mutation of AKT1 in human cancer tumors: it was discovered in clinical samples from cancer patients, yet has never been detected in cancer cell lines.

"This discovery is a seminal finding in cancer biology that confirms AKT1 as an oncogene in breast, colorectal and ovarian cancer. The mutation alters the electrostatics of binding pocket in the pleckstrin homology domain, the portion of the enzyme that docks with phospholipids on the cell membrane," said Kerry L. Blanchard, PhD, MD, Executive Director, Discovery Biology Research, Eli Lilly & Company.

To identify the AKT1 mutation, the researchers analyzed 150 tumor samples from patients with either breast, colorectal or ovarian cancer (50 samples from each tumor type). Analysis of the data showed that 8 percent of breast, 6 percent of colorectal and 2 percent of ovarian tumors had the AKT1 mutation in the samples that were screened in their study.

"Recently, molecular features such as the AKT1 mutation are beginning to change drug development efforts. This discovery adds to the short but growing list of molecular features that may help guide both current and future cancer drug development," said John Carpten, PhD, Senior Investigator and Director of TGen's Integrated Cancer Genomics Division and the study's lead author. "The next step is to determine the prevalence of the AKT1 mutation in different populations and, hopefully, use the information gained to stratify patients going into clinical trials for AKT inhibitors."

If validated by further studies, the identification of this recurring mutation has the potential to impact cancer treatment and drug development.

"This is a gorgeous study that used a variety of sophisticated techniques to provide new insights into the tumorigenic process," said Bert Vogelstein, MD, Director of the Ludwig Center for Cancer Genetics & Therapeutics at The Johns Hopkins Kimmel Cancer Center.

James E. Thomas, PhD, of Lilly's Cancer Discovery Research division, explained, "AKT1 is a protein kinase or enzyme that plays a key role in activating survival, proliferation and metabolic pathways. Interestingly, other cellular proteins that regulate this network have also been shown to be mutated in a variety of cancers including lung, breast ovary, prostate, colorectal and brain cancers. This mutation in AKT1 is striking direct evidence for the role of AKT1 in cancer formation."

The identification of the AKT1 mutation was a collaborative effort between Eli Lilly & Company and TGen. "This discovery demonstrates the importance of studying the genetic make up of cancers at the clinical level rather than relying on model systems," adds Jeffrey Trent, PhD, Scientific Director of TGen.

"This is a key study highlighting Lilly’s commitment to translational research approaches in cancer drug discovery and development. Furthermore, this work is a great example of a successful public-private partnership at a global level that involves Lilly Research Laboratories in Indianapolis, TGen in Phoenix, Lilly Singapore Centre for Drug Discovery, and the Economic Development Board of Singapore", adds Richard Gaynor, MD, Vice President of Oncology Discovery at Eli Lilly & Company. He added, "This mutation further validates AKT1 as an attractive drug target, and it also will be a valuable tool for the stratification of patients for targeted therapies. This paradigm of identifying specific defects in cancer cells to successfully develop innovative therapies has been validated with oncology drugs such as Gleevec in leukemia and Herceptin in breast cancer."


About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About TGen
The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, is focused on developing earlier diagnoses and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research.


Biotechnology Marketing

GPC Biotech GPCB Pharmion Corporation PHRM



Biotech News
GPC Biotech Announces that Partner Pharmion Submits European Marketing Application for Satraplatin


GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX
index; Nasdaq: GPCB) today announced that its partner, Pharmion Corporation
(Nasdaq: PHRM), has submitted a Marketing Authorization Application (MAA)
to the European Medicines Agency (EMEA) for satraplatin in combination with
prednisone for the treatment of patients with metastatic hormone refractory
prostate cancer (HRPC) who have failed prior chemotherapy. This filing is
based primarily on data from the SPARC Phase 3 registrational trial.


"We are delighted that Pharmion has submitted the European marketing
application for satraplatin," said Bernd R. Seizinger, M.D., Ph.D., Chief
Executive Officer. "With over 60,000 people expected to die from prostate
cancer in the European Union this year, there is an urgent need for new
therapies. We believe that, if approved, satraplatin has the potential to
become an important new treatment option for advanced prostate cancer
patients who today have very little hope."


GPC Biotech will receive an $8 million milestone payment from Pharmion
in connection with EMEA's acceptance of this filing. Under the terms of GPC
Biotech's agreement with Spectrum Pharmaceuticals, the acceptance of the
MAA by the EMEA will also trigger payments by GPC Biotech to Spectrum in a
total amount of $3.2 million, representing a direct milestone payment plus
Spectrum's share of the $8 million milestone payment from Pharmion.


AZhttp, Inc.

Biotechnology Marketing

Biotechnology Industry Organization BIO

Biotech News


Industrial Biotechnology Is Key to Achieving Energy Independence, BIO Says
Congress’ Energy Independence Day Initiative Should Focus on Tax Incentives, Renewable Fuel Standard and Biofuel Infrastructure

Brent Erickson, executive vice president of the Biotechnology Industry Organization’s (BIO) Industrial & Environmental Section, released the following statement today regarding Energy Independence Day legislation highlighted by House leaders:

“As Americans celebrate Independence Day, they can expect to hear politicians of every stripe advocate domestically produced biofuels – particularly ethanol from cellulose – as the surest route to greater energy independence. We agree that biofuels can help America drastically lessen its dependence on foreign petroleum imports. In fact, ongoing advances in industrial and agricultural biotechnology can help America meet nearly half its transportation-fuel needs by the middle of this century. And Congress could do a great deal to help American companies achieve this goal.

“What most Americans don’t realize is that pioneering companies around the country are right now planning to build biorefineries to bring cellulosic ethanol to the pump, if the proper incentives are available. Many of these biorefineries will be built through public-private partnerships, with industrial biotechnology companies at the forefront. Leading biotechnology companies and biofuel producers are major participants in many U.S. Department of Energy projects announced this year, including the recently named Biofuels Research Centers. Through their work, the first few million gallons of ethanol from cellulose will become available to U.S. consumers by the end of 2007.

“But a few simple facts illustrate the need for much more rapid commercialization of biofuels from cellulose. The existing Renewable Fuel Standard (RFS) calls for 250 million gallons of cellulosic biofuels by 2013. However, capacity for cellulosic ethanol production from all biorefineries currently planned or under construction is approximately 128 million gallons.

“The ‘Renewable Fuels, Consumer Protection, and Energy Efficiency Act of 2007’ recently passed by the Senate proposes a new RFS of 36 billion gallons, including 21 billion gallons of cellulosic biofuel, by 2022. Under this new standard, renewable fuels would meet just over 20 percent of expected demand for transportation fuels.

“To rapidly achieve a level of cellulosic biofuel production that will substantially lessen U.S. dependence on imported energy, the biofuels industry needs continued investment both in construction of large-scale biorefineries and in ongoing research and development in enzymes and other biorefinery processes. Congress can help the industry in three ways. First, the proposed new RFS will help to create market demand for cellulosic biofuels. Second, a tax credit for pioneering producers would help the industry overcome the increased risk associated with bringing cellulosic biofuels to the marketplace. And third, development of infrastructure to transport, store and pump biofuels would help the industry bring the benefits of biofuels directly to consumers.

“We need not only a new renewable fuel standard, but also the other policy tools that will insure rapid construction of large-scale commercial cellulosic biofuels facilities. There will be considerable business risk for the pioneer cellulosic biorefineries and Congress must help insure that these risks are reduced so that we can meet the requirements of a new RFS. The Senate passed an energy tax bill that the oil companies derailed. Let’s hope, in the interest of changing our energy mix, the House will be able to pass a cellulosic biofuels tax credit and that the Senate and President will support it.”

For more information on cellulosic biorefineries under construction, please visit http://bio.org/ind/biofuel/CellulosicEthanolIssueBrief.pdf.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

AZhttp, Inc.